中国生物工程杂志

［1］ Morrison S L, Johnson M J, Herzenberg L A, et al. Chimeric human antibody molecules: Mouse antigenbinding domains with human constant region domains. Proc Natl Acad Sci USA, 1984, 81: 6851~6855
［2］ 沈倍奋，陈志南，刘民培. 重组抗体. 北京：科学出版社，2005.217~234
Shen B F, Chen Z N, Liu M P. Beijing: Science Press,2005.217~234
［3］ 沈倍奋. 抗体药物研究进展. 第二军医大学学报, 2002, 23 (10): 1047~1049
Shen B F. Acad J Sec Mil Med Univ, 2002, 23 (10): 1047~1049
［4］ Booy E P, Johar D, Maddika S,et al. Monoclonal and bispecific antibodies as novel therapeutics.
［5］ 陈志南. 基于抗体的中国生物制药产业化前景. 中国医药生物技术, 2007, 2 (1): 2~5
Chen Z N. Chin Med Biotechol, 2007, 2 (1): 2~5
［6］ Hwang W Y, Foote J. Immunogenicity of engineered antibodies. Methods, 2005, 36 (1):3~10
［7］ Kashmiri S V, De Pascalis R, Gonzales N R, et al. SDR grafting——a new approach to antibody humanization. Methods, 2005, 36 (1):25~34
［8］ Clark M. Antibody humanization: a case of the ‘Emperor’s new clothes’? Immunol Today, 2000, 21 (8):397~402
［9］ Leonard J P, Coleman M, Ketas J C, et al. Epratuzumab, a humanized antiCD22 antibody, in aggressive nonHodgkin’s lymphoma. Clin Cancer Res, 2004, 10 (16): 5327~5334
［10］ 中国首个基因重组人源化单克隆抗体药物上市. 中国医药生物技术. 2008, 3 (5): 384
Chin Med Biotechol, 2008, 3 (5): 384
［11］ Haymes L M, Tonkin J, Anderson L J, et al. Neutralizing antiF glycoprotein and antisubstance  Pantibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection. J Virol, 2002, 76 (14): 6873~6881
［12］ Lambert M P, Barlow A K, Chromy B A, et al. Diffusible, nonfibrillar ligands derived from Abeta142 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A, 1998, 95 (11):6448~6453
［13］ Bard F, Cannon C, Barbour R, et al.Peripherally administered antibodies against amyloid betapeptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med, 2000, 6 (8):916~919
［14］ Lee E B, Leng L Z, Zhang B, et al. Targeting amyloidbeta peptide (Aβ) oligomers by passive immunization with a conformationselective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J Biol Chem, 2006, 281 (7):4292~4299
［15］ Hawkes C A, McLaurin J. Clinical immunotherapy trials in Alzheimer’s disease. Drug Discovery Today: Therapeutic Strategies, 2008(in press)
［16］ Wilcock D M, Colton C A. Antiamyloidbeta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis, 2008, 15 (4):555~569
［17］ Thakker D R, Weatherspoon M R, Harrison J, et al. Intracerebroventricular amyloid{beta} antibodies reduce cerebral amyloid angiopathy and associated microhemorrhages in aged Tg2576 mice. Proc Natl Acad Sci U S A, 2009, 25(in press)
［18］ Weinblatt M E, Keystone E C, Furst D E, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. Ann Rheumatic Dis, 2006, 65 (6): 753~759